Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

MLA

Anders Själander, et al. “Combination of Pegylated IFN-Α2b with Imatinib Increases Molecular Response Rates in Patients with Low- or Intermediate-Risk Chronic Myeloid Leukemia.” Blood, vol. 118, Sept. 2011, pp. 3228–35. EBSCOhost, https://doi.org/10.1182/blood-2011-02-336685.

APA

Anders Själander, Johan Lanng Nielsen, Henrik Hjorth-Hansen, Satu Mustjoki, Kari Remes, Hans Ehrencrona, Ole Weiss Bjerrum, Anders Almqvist, Mats Björeman, Berit Markevärn, Fredrik Sandin, Franz Gruber, Kristina Myhr-Eriksson, Claes Malm, Max Flogegard, Arnon Nagler, V Kairisto, Ulla Strömberg, Perttu Koskenvesa, … Anu Räsänen. (2011). Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood, 118, 3228–3235. https://doi.org/10.1182/blood-2011-02-336685

Chicago

Anders Själander, Johan Lanng Nielsen, Henrik Hjorth-Hansen, Satu Mustjoki, Kari Remes, Hans Ehrencrona, Ole Weiss Bjerrum, et al. 2011. “Combination of Pegylated IFN-Α2b with Imatinib Increases Molecular Response Rates in Patients with Low- or Intermediate-Risk Chronic Myeloid Leukemia.” Blood 118 (September): 3228–35. doi:10.1182/blood-2011-02-336685.